Invivyd to Participate at the Jefferies Global Healthcare Conference
Invivyd (Nasdaq: IVVD), a biopharmaceutical company focused on viral infectious diseases, announced its participation in the Jefferies Global Healthcare Conference on June 6, 2024, at 3:00 p.m. ET in New York. The company will engage in a fireside chat and host investor meetings. A live webcast of the chat will be available on Invivyd's investor website and archived for 30 days.
- Participation in the Jefferies Global Healthcare Conference increases visibility.
- Fireside chat and investor meetings provide engagement opportunities.
- Live webcast extends the reach of the presentation to a broader audience.
- The PR lacks specific financial or clinical updates.
WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET in New York, NY.
In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the conference who are interested in meeting with Invivyd management should contact their Jefferies representative.
A live webcast of the fireside chat will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 30 days following the presentation.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Contacts:
Media Relations
(781) 208-0160
media@invivyd.com
Investor Relations
(781) 208-0160
investors@invivyd.com
![](https://ml.globenewswire.com/media/NDYwOWZmMWYtYzY4Yi00MDM1LWIxMmQtNGY3ZmM3ODc3OWQxLTEyMjEzMTQ=/tiny/Invivyd.png)
FAQ
What is Invivyd's stock symbol?
When is Invivyd participating in the Jefferies Global Healthcare Conference?
How can investors watch the live webcast of Invivyd's fireside chat?
Will the webcast of Invivyd's fireside chat be available after the event?